Status:
COMPLETED
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Adenocarcinoma
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the...
Eligibility Criteria
Inclusion
- Breast Cancer Stage T1-3, N1, M0
- Suitable candidate for anthracycline-containing adjuvant chemotherapy
Exclusion
- Evidence of residual tumor following surgery, or metastatic disease
- Received prior therapy for breast cancer
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
606 Patients enrolled
Trial Details
Trial ID
NCT00140075
Start Date
November 1 2000
End Date
August 1 2006
Last Update
May 26 2011
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
2
Pfizer Investigational Site
Tucson, Arizona, United States, 85712
3
Pfizer Investigational Site
Bakersfield, California, United States, 93309
4
Pfizer Investigational Site
Berkeley, California, United States, 94704